Core Viewpoint - Haishun New Materials has experienced fluctuations in stock price and financial performance, with a notable decrease in net profit year-on-year, indicating potential challenges in the market [1][2]. Financial Performance - As of September 30, 2025, Haishun New Materials reported a revenue of 823 million yuan, a year-on-year decrease of 0.42% [2]. - The net profit attributable to shareholders was 48.67 million yuan, reflecting a significant year-on-year decline of 38.96% [2]. - The company has distributed a total of 296 million yuan in dividends since its A-share listing, with 139 million yuan distributed over the past three years [3]. Stock Market Activity - On November 27, the stock price increased by 2.12%, reaching 16.35 yuan per share, with a trading volume of 24.93 million yuan and a turnover rate of 1.23% [1]. - The total market capitalization of Haishun New Materials is 3.164 billion yuan [1]. - Year-to-date, the stock price has risen by 24.92%, but it has seen a decline of 4.27% over the last five trading days [1]. Shareholder Information - The number of shareholders as of September 30, 2025, is 13,500, a decrease of 12.81% from the previous period [2]. - The average number of circulating shares per shareholder is 9,274, which has increased by 14.69% [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 717,800 shares [3]. Company Overview - Haishun New Materials, established on January 18, 2005, specializes in the research, production, and sales of high-barrier packaging materials that come into direct contact with pharmaceuticals [1]. - The company's main business revenue composition is 89.58% from new pharmaceutical packaging materials and 10.42% from other sources [1]. - The company operates within the light industry manufacturing sector, specifically in packaging and printing [1].

Core Insights - Haishun New Materials is a leading enterprise in the high-barrier packaging materials sector directly in contact with pharmaceuticals, established in 2005 and listed on the Shenzhen Stock Exchange in 2016 [1] Group 1: Business Performance - In Q3 2025, Haishun New Materials achieved a revenue of 823 million yuan, ranking first among six companies in the industry, with the second-ranked Tianyuan Co. generating 767 million yuan [2] - The revenue from new pharmaceutical packaging materials was 495 million yuan, accounting for 89.58% of total revenue, while other business revenue was 57.5 million yuan, making up 10.42% [2] - The net profit for the same period was 54.42 million yuan, placing the company second in the industry, with the first being Jinghua Laser at 73.13 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, the asset-liability ratio for Haishun New Materials was 38.56%, higher than the previous year's 34.82% and above the industry average of 37.97% [3] - The gross profit margin was 22.93%, down from 29.69% year-on-year but still above the industry average of 14.09% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 12.81% to 13,500, while the average number of circulating A-shares held per account increased by 14.69% to 9,274.86 [5] - The top ten circulating shareholders included a new entrant, the Medical Device ETF (159883), holding 717,800 shares [5] Group 4: Executive Compensation - The chairman and general manager, Lin Wuhui, received a salary of 912,300 yuan in 2024, a slight increase from 912,000 yuan in 2023 [4]